Trial reportCancer discovery2020
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Open access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 271 papers.
0numbers the graph read from it
0cells of the map it votes in
271citing papers in PubMed
30.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
271 citing papers in PubMed, 412 citations in OpenAlex.
- HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial).Signal transduction and targeted therapy · 2026Trial
- ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer.Nature communications · 2026Trial
- Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.Nature communications · 2026Trial
- Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.JCO precision oncology · 2025Trial
- Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.Nature communications · 2024Trial
- Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial.JCO precision oncology · 2024Trial
- Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.The New England journal of medicine · 2023Trial
- Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.JAMA oncology · 2023Trial
- Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Next-generation CDK inhibitors in HR+/HER2- breast cancer.The Journal of clinical investigation · 2026Review
- A noncanonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer.Science advances · 2026Article
- Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Clustered structural variant hotspots enable oncogenic addiction and plasticity in osteosarcoma.bioRxiv : the preprint server for biology · 2026Article
- Targeting casein kinase 1α-mediated FADD phosphorylation restores sensitivity in select CDK4/6 inhibitor-resistant breast cancer models.The Journal of clinical investigation · 2026Article
- Cyclins and Cyclin-Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer.MedComm · 2026Review
- CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities.Targeted oncology · 2026Review
- Article
- Time-resolved proteomic and phosphoproteomic analysis reveals convergent and divergent biological perturbations induced by FDA-approved CDK4/6 inhibitors in hormone receptor-positive breast cancers.Acta pharmacologica Sinica · 2026Article
211 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 6 institutions in 2 countries.
Seth A Wander *Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
Ofir Cohen *Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
Xueqian Gong *Eli Lilly and Co., Indianapolis, Indiana.
Gabriela N JohnsonCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jorge E Buendia-BuendiaCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
Maxwell R LloydCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID https://orcid.org/0000-0001-9810-0437
Dewey KimCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
Flora LuoCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
Pingping MaoCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
Karla HelvieCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kailey J KowalskiCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
Utthara NayarCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID https://orcid.org/0000-0002-9024-6084
Adrienne G WaksCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID https://orcid.org/0000-0001-5649-7229
Stephen H ParsonsEli Lilly and Co., Indianapolis, Indiana.
Ricardo MartinezEli Lilly and Co., Indianapolis, Indiana.
Lacey M LitchfieldEli Lilly and Co., Indianapolis, Indiana.
Xiang S YeEli Lilly and Co., Indianapolis, Indiana.
Chunping YuEli Lilly and Co., Indianapolis, Indiana.
Valerie M JansenEli Lilly and Co., Indianapolis, Indiana.
John R StilleEli Lilly and Co., Indianapolis, Indiana.ORCID https://orcid.org/0000-0001-6397-154X
Patricia S SmithEli Lilly and Co., Indianapolis, Indiana.
Gerard J OakleyEli Lilly and Co., Indianapolis, Indiana.
Quincy S ChuCross Cancer Institute, Alberta, Canada.
Gerald BatistSegal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Canada.
Melissa E HughesCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jill D KremerEli Lilly and Co., Indianapolis, Indiana.
Levi A GarrawayCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
Eric P WinerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID https://orcid.org/0000-0002-8819-1723
Sara M TolaneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Nancy U LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID https://orcid.org/0000-0003-2263-5413
Sean G BuchananEli Lilly and Co., Indianapolis, Indiana.ORCID https://orcid.org/0000-0002-5215-4672
Nikhil WagleCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts. nikhil_wagle@dfci.harvard.edu.
Broad Institute · USEli Lilly (United States) · USDana-Farber Cancer Institute · USHarvard University · USInstitute of Cancer Research · CAJewish General Hospital · CA
Funding
Tissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI LEIF W ELLISEN, NANCY U LIN · 2013 to 2026
$30.1MVanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MNCI NIH HHS K12 CA090625NCI NIH HHS P50 CA168504
Abstract
Mechanisms driving resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR
Indexed as
Antineoplastic AgentsBiopsyBreast NeoplasmsCell Cycle ProteinsCell Line, TumorCheckpoint Kinase 1Drug Resistance, NeoplasmExome SequencingFemaleGenomicsHumansProtein Kinase InhibitorsProto-Oncogene Proteins c-aktProto-Oncogene Proteins p21(ras)Receptors, SteroidRetinoblastoma Binding ProteinsAKT1 protein, humanAntineoplastic AgentsCell Cycle ProteinsCheckpoint Kinase 1CHEK1 protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-aktProto-Oncogene Proteins p21(ras)RB1 protein, humanReceptors, SteroidRetinoblastoma Binding ProteinsUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.